In a recent editorial in Biocompare, Emma Mason highlights the technologies transforming single-cell sorting – and at Sphere Bio, we are proud to be at the forefront of that evolution.

Our Cyto-Mine® platform leverages picodroplet microfluidics to encapsulate individual cells into ultra-miniaturized reaction vessels, enabling real-time, high-throughput analysis, sorting, imaging, and dispensing—all in one integrated workflow. This makes it possible to rapidly identify high-performing clones, especially for applications like monoclonal antibody (mAb) development.

As Maryam Ahmadi, Ph.D., Director of Science, explains:

To support the future of multiplexed screening, we’ve also introduced Cyto-Mine® Chroma. Featuring four lasers and four detection channels, Cyto-Mine® Chroma brings advanced multiplexing and sensitivity to early-stage therapeutic development.

We’re excited to see Cyto-Mine® Chroma enabling researchers to streamline clone selection, reduce manual intervention, and bring more informed decisions to the earliest stages of development.

For more insights on the latest developments in biologics and cell line research, visit Sphere Bio’s Knowledge Hub or or dive into our Cyto-Mine® Chroma solution for early-stage screening.

This article is part of our Editorial Coverage series, showcasing Sphere Bio’s thought leadership and technological contributions in top-tier industry publications. Stay tuned for more.